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Introduction
Schizophrenia has been conceptualised as a neurodevelopmentally mediated, cognitive illness marked by a more unfavourable outcome than affective disorders (1) . Positive and negative symptoms and cognitive dysfunction are core features of the illness; however, there is a phenomenological overlap between schizophrenia and mood disorders (2) ; mood symptoms are common features in prodromal psychosis and established schizophrenia (3) , while psychotic symptoms frequently occur with severe mood disorders. Such observations, as well as burgeoning biological evidence (4, 5) , challenge the Kraepelinian dichotomy. One area of perhaps neglected phenomenological enquiry is negative symptoms; negative symptoms may present variously as a loss of motivation to act and a lack of the elements that make up the normal repertoire of social and emotional responsiveness (6) , yet these are also commonly seen in depression (7) .
Andreasen (8) characterised negative symptoms as consisting of affective blunting or flattening, alogia, anhedonia/asociality and avolition/apathy and attention, although attentional deficits may indicate cognitive impairment rather than a manifestation of a negative symptoms. Much of the earlier research exploring negative symptoms has assumed that they form one discrete syndrome. However, factor analyses have isolated two subdomains within negative symptoms (9, 10) , namely avolition-amotivation and expressive deficits. The avolition-amotivation subdomain is considered to be formed of the symptoms, avolition, asociality and anhedonia, whereas the diminished expression subdomain comprises blunted affect and alogia (11) (12) (13) .
Depression is a mood disorder that is characterised by low mood and anhedonia (14) . Affective symptoms have been recognised as occurring commonly in non-affective psychosis, in 50%-80% of patients at some point during their illness (15, 16) . Previously, Siris et al. (17) found that half of individuals with postpsychotic depression also met criteria for negative symptoms, implying a syndromal overlap between depressive and negative symptoms. However, Addington et al. (18) designed the Calgary Depression Scale for Schizophrenia to assess depression separately from negative symptoms and also from positive symptoms and extrapyramidal symptoms such as Parkinsonism.
Previous models have conceptualised depression and negative symptoms as belonging to distinct and separate clinical syndromes (19) (20) (21) (22) (23) . Within a dimensional approach to psychoses, a model of overlapping domains with distinct presentations allows further exploration of the heterogeneity involved. Initially presented as three domains of reality distortion, psychomotor poverty and disorganization syndrome (24) , more recently mood symptoms have been included in five factor models; positive symptoms, negative symptoms, depression, mania and cognitive (25) . These models of symptoms of psychoses allow for comorbidity in more than one domain, with an individual patient presenting with varying degrees of symptom severity in each domain.
The exact nature of the relationship between depression and negative symptoms in a 'non-affective' psychotic illness such as schizophrenia remains uncertain. Identifying depression in schizophrenia and treating this symptom domain is essential given that depression in schizophrenia has been associated with poor prognosis and suicide (3, 26) . Understanding this heterogeneity further is potentially important for the elucidation of the underlying aetiological mechanisms and the development of better, targeted, treatments.
Aim of the study
The aim of this systematic review was to provide a novel and up-to-date review of the evidence for the phenomenological co-occurrence of depression and negative symptoms in schizophrenia.
Method
A systematic search and review following the PRISMA guidelines (27) was conducted. We limited our search to studies examining depression and negative symptoms in schizophrenia and excluded studies looking at other conditions. There were no limits put on the origin or date of a publication.
Inclusion criteria Table S1 for the full search strategy).
Two reviewers (CRK and RU) independently reviewed all the papers screened and agreed on which papers should be included in the review (see Table 1 ).
Results
A total of 2210 articles were identified. Following the removal of 892 duplicates, the titles and abstracts of the remaining 1320 articles were screened, and 75 were found to be potentially relevant. Of those 75 papers, read in full, 25 papers met the inclusion criteria and were eligible for the review. References cited in the papers were handsearched, which yielded two further eligible articles, bringing the total number of studies included to 27 (see Fig. 1 ).
Study characteristics
Sampling. Thirteen papers reported on samples from in-patient units (16, 29, 32-34, 36-38, 41, 42, 44, 46, 47) , while nine of the studies examined patients in community settings (15, 28, 30, 39, 40, (48) (49) (50) (51) . One study (22) included participants from both in-patient and out-patient units, while the remaining four studies did not provide information on the source of the patient sample (31, 43, 45, 52) . The study sample sizes ranged from 42 to 921 participants, with a total number of 3062.
Rating scales used. Depression scales. The majority of studies employed a single scale to assess symptoms of depression, with the most commonly used being either the Hamilton Rating Scale for Depression (16, 22, 28, 33, 36-38, 40, 41, 52) . Six studies used the Calgary Depression Scale for Schizophrenia (CDSS) (15, 42, 45, 48, 49, 51) , and five studies used the Beck Depression Inventory (22, 29, 30, 40) .
Negative symptom scales. The majority of studies used either Scale for the Assessment of Negative Symptoms (SANS) (8) or the negative subscale of the Positive and Negative Syndrome Scale (PANSS) (53) to assess negative symptoms; (15, 16, 22, 28-31, 34, 36-45, 48, 49, 52) . Five studies (31, 33, 39, 41, 51) used the negative subscale of the Brief Psychiatric Rating Scale (BPRS) (54). Romney et al. (22) rated anhedonia separately using Physical Anhedonia Scale (PAS) (55) and Social Anhedonia Scale (SAS) (56) .
Study design and analysis. The majority of studies employed a cross-sectional design (22, 28-31, 34, 36, 39, 40, 42, 45-51) . One study adopted a prospective design (16) . One study employed a combined prospective and retrospective study design (15) and four studies implemented a prospective, longitudinal study design (32, (37) (38) (39) . One study reported on a cross-sectional and longitudinal arm (44) . An experimental design was used by two studies included in the review; Oosthuizen et al. (43) Prevalence and reporting of negative symptoms and depression. The prevalence of depression in the studies reviewed ranged from 30% to 80%, depending on the criteria for the presence of depression (46, 52) or depressive symptoms (15, 16, 39, 41, 43, 45, 47, 49 ) that were used.
Factor analysis was reported by two studies, which described a depression domain independent from negative symptoms and positive symptoms (22, 50) . Symptoms such as low mood, pessimism, suicidal ideation and impaired tolerance to stress were considered depressive features (31, 34) . The negative symptom domain included alogia, poor attention and concentration, blunted affect and social withdrawal (28) . Anhedonia, emotional blunting, anergia, amotivation, asociality and avolition occurred in both the negative and depressive domains (22, 28, 36) .
Results from all of the studies reviewed were tabulated into symptoms that were reported as distinct depressive features, symptoms that were distinct negative symptoms and symptoms that overlapped between the two symptom domains (see Table 2 ).
Discussion
The findings of the studies reviewed suggest while considerable heterogeneity is present, some depressive features such as low mood, suicidal ideation, pessimism are distinct from a negative symptom domain characterised by alogia and blunted affect in schizophrenia. For example, Liemburg et al. (10) and Messinger et al. (9) found that while depressed mood and suicidal intent reflect a depressive domain, blunted affect and alogia belong to the 'expressive-deficit' negative symptom domain. Symptoms such as avolition, anergia and amotivation, considered to constitute 'social amotivation', appear to occur in both the depressive and negative domains. The findings presented are consistent with those of Whiteford et al. (28) , who emphasised that while symptoms such as alogia and poor attention were distinctly negative symptoms, loss of energy and anhedonia were present in both the depressive and negative domains. Observed sadness together with inability to feel was reported as a negative symptom by Kibel et al. (34) as distinguished from subjective sadness. However, this was not replicated by other studies. One explanation for this finding is that there can be a misattribution of blunted affect or lack of facial expression as observed sadness. Sax et al. (36) found the co-occurrence of depressive and negative symptoms to be confined to poor motivation, anhedonia and social withdrawal, but this may be artefactual, specifically the product of similarly worded items on different rating scales. The findings relating to whether anhedonia should be considered as part of the negative symptom or depressive symptom domains are inconsistent, and our results suggest anhedonia occurs in both. Evidence from factor analysis studies suggests that anhedonia may be more closely aligned with depression rather than schizophrenia (22, 45) . Alternatively, it has been considered as a negative symptom of schizophrenia because of its close relationship with blunted affect, emotional blunting and social withdrawal (22) .
The inconsistency of classification of anhedonia may partly reflect that anhedonia may be a feature of negative and depressive domains in schizophrenia in different forms, differentiated by distinguishing between anticipatory and consummatory anhedonia. Thus, anhedonia as part of depression may reflect a loss of interest in previously rewarding or enjoyable activity because of the inability to experience pleasure. However, individuals with schizophrenia may experience normal levels of pleasure when engaging in enjoyable activities (consummatory pleasure) but lack the ability to experience pleasure for future activities (anticipatory pleasure), and therefore have an anticipatory anhedonia but not a consummatory anhedonia (58) . These may reflect differing underlying processes; abnormal psychological and dysfunctional behavioural processes that are responsible for differing manifestations of anhedonia (59) . However, when Li et al. (60) observed people with moderate depressive disorder and individuals with schizophrenia, they found anticipatory and consummatory anhedonia were present in both conditions. Furthermore, Buck et al. (61) observed strong correlations between scores of consummatory and anticipatory anhedonia in schizophrenia, suggesting that the explanatory value of this distinction regarding anhedonia as a negative or depressive symptom may be limited (61) . However, the notion that anhedonia as a negative symptom has a different pathophysiology from its presentation as a depressive symptom is speculative and further research is needed to address this. Furthermore, the findings prompting such a notion may simply reflect a limitation in the scales used to assess the change of hedonic experiences in patients with schizophrenia.
A dimensional model within domains
If we consider negative symptoms as being formed of a diminished expression domain and avolitionamotivation subdomain (9) , the presented findings suggest that the relationship is primarily between depression and avolition-amotivation phenomena. The relationship between depressive and negative symptoms may be represented in a dimensional model (see Fig. 2 ), with symptoms denoting general, attenuated non-specific symptoms; those that span both depressive and negative symptoms (such as anergia and poverty in speech) and those that represent specific symptoms of depression (such as consummatory anhedonia, hopelessness) and negative symptoms (such as anticipatory anhedonia, blunted affect). Levels within a dimensional hierarchy have often been implied in a positive domain, for example social anxiety/subtle self-referential thinking building to brief attenuated symptoms followed by frank delusional beliefs and hallucinations (see Mishara et al. (62) .
In our model, symptoms that form the expressive deficits subdomain appear to be specific to negative symptoms and are represented by '3' in the negative symptom domain of our dimensional model. Symptoms such as low mood, suicidal ideation and pessimism are considered core features of depression and are denoted by '3' in the depression domain. Symptoms that form the avolition-amotivation subdomain of negative symptoms appear to consist of features that span both depressive and However, only one of the studies (50) employed a scale that allows for the distinction between the two negative symptom subdomains (the Brief Negative Symptom Scale) (63) . This highlights the importance of future studies using scales able to assess the distinction between the subdomains that form negative symptoms, such as the Clinical Assessment Interview for Negative Symptoms (CAINS: 64). This would have particular implications for studies assessing the effectiveness of domain-specific interventions.
Limitations
Studies included were markedly heterogeneous; both medicated and unmedicated patients were included in the study samples as well as broad diagnostic groups including schizophrenia and first-episode psychosis. There was also a lack of consistency regarding the methods used to assess depression and negative symptoms. It can be argued that the SANS (8) provides the most comprehensive and valid coverage of negative symptom domains in schizophrenia and is highly tuned to detecting differences between positive and negative symptoms in schizophrenia, yet it was not universally used. However, the use of the SANS has its limitations not least the item assessing attention, which may be considered a manifestation of cognitive dysfunction and not form part of the negative syndrome. Nevertheless, no phenomenological measure has been developed that is able to differentiate between primary and secondary negative symptoms, and the subjective experiences related to negative symptoms are not elicited (65) (66) (67) . Also, to measure depression, some studies used the HRSD (22) , others used the CDSS (15) and some others used the BDI (40) .
Implications
The DSM RDoC criteria and NIMH objectives recommend that research studies should focus increasingly on specific indicative symptoms to ascertain treatment effects (68, 69) . Our review has suggested a putative model (see Fig. 2 ) which could be used as a starting point for the investigation underlying biological processes and targeted treatment within a dimensional psychosis model (70) (71) (72) . Being able to clinically distinguish between depressive and negative symptoms in schizophrenia would not only allow for early, targeted treatment, but may also provide some indication of a patient's symptom burden and possibly have implications for prognosis, which can then be used to help inform a tailored treatment plan. Discriminating between anticipatory and consummatory anhedonia may prove to be a useful distinction in relation to association with either the depressive or negative domain which would suggest that the two domains within anhedonia (consummatory and anticipatory) may be products of differing aetiology.
Distinguishing between these two domains may provide clinical benefit through targeted therapy, which can be directed at either anticipatory or consummatory anhedonia and has been shown to be effective when applying psychological therapy (73) . To date, there have been relatively few studies assessing the use of antidepressants to treat depression in schizophrenia and those that have been reported yielded mixed results, possibly the result of poor understanding of the core symptoms of depression therein (74-78) Furthermore, to understand the relationship between depression and negative symptoms in schizophrenia, highly sensitive measures and thorough longitudinal studies, which chart symptom development and course, are required.
